Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

Share Price is delayed by 15 minutes
Get Live Data
72.80    2.20 (3.13%)
Bid:
71.00
Ask:
74.60
Spread: 3.60 (5.07%)
Market Cap: £91.33m
GCL Live PriceLast checked at - London Stock Exchange

Intraday Geiger Counter Share Chart

Monthly Factsheet- June 2025

23 Jul 2025 17:13

RNS Number : 3048S
Geiger Counter Ltd
23 July 2025
 

 

 

Geiger Counter Limited Plc 

 

Monthly Investor Report 23 July 2025

(All Factsheet data is at 30 June 2025)

 

The full monthly factsheet is now available on the Company's website and a summary can be found below. 

 

NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd

 

 

Enquiries: 

 

For the Investment Manager 

Craig Cleland 

Manulife CQS Investment Management

0207 201 5368 

For the Company Secretary and Administrator 

R&H Fund Services (Jersey) Limited

Jane De Barros/Katie De La Cour

01534 825259/01534 825337 

 

----------------------------------------------------------------------- 

 

 

Fund Description 

 

The objective of Geiger Counter Limited is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource- related companies from outside the energy sector.

 

Portfolio Managers 

 

Keith Watson and Robert Crayfourd 

 

 

Key Advantages for the Investor 

· Access to mining assets in the uranium sector

· May benefit from embedded subscription share

· Low correlation to major asset classes

 

 

 

Key Fund Facts1 

 

 

Total Gross Assets 

£71.7m

Reference Currency 

GBP 

Ordinary Shares: 

Net Asset Value 

50.31 

Mid-Market Price  

43.80p 

Net gearing4 

21.50% 

Discount 

(12.94%) 

 

 

Ordinary Share and NAV Performance2 

 

 

One Month 

Three Months 

One Year 

Three Years 

Five Years 

 

(%) 

(%) 

(%) 

(%) 

(%) 

NAV 

18.35 

46.72

(20.10) 

23.98

238.10

Share Price 

9.50

29.97 

(11.52)

10.19 

171.21 

 

 

Commentary3 

 

The Company's NAV rose 18.4% over the month against a stronger uranium price backdrop. The spot U3O8 price ended the month up 3.7% at $74.3/lb with support arising after a $200m equity placement by the Sprott Physical Uranium Trust for the purpose of acquiring more material. The Company's return compared to a sterling gain of 18.0% registered by the Solactive Uranium Pure Play Index.

 

Early in the month, first Meta and then Amazon announced that they had formalised long-term

nuclear power purchase agreements with Constellation Energy and Talen Energy respectively to power their data centres, helping buoy sentiment. Subsequently, the Sprott Uranium Trust

continued to buy uranium, funded by its upsized equity issue which allowed it to purchase nearly 1.5Mlbs of U3O8 during June, taking its total holding towards 68Mlbs by the end of the month.

 

Nexgen made a strong contribution to performance with the share price rising nearly 12% in June. Encouragingly, the incoming and pro-nuclear Canadian government held a conference among its top ministers to assess projects of national strategic importance. This included energy and critical minerals, a move which would appear supportive for the future development of Nexgen's globally significant Arrow project in Saskatchewan. The development is awaiting its final court hearings, currently scheduled to take place in early 2026. Elsewhere, Ur-Energy also made a strong contribution, with the shares rising over 28% over the month, as the group continues to ramp-up production from the restarting Lost Creek ISR Project. Paladin and Cameco were also helpful with their share prices rising 29% and 26% respectively.

 

 

 

 

 

 

 

Gross Leverage6

(%)

 

 

 

 

Commitment Leverage7

(%)

Geiger Counter Ltd 

122

122

 

 

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

 

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

 

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

 

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary. 4 BMO, UxC, Company data September 2023. 5 www.eia.gov. 6CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013. 7CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 231/2013.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCMZGZNVFZGKZM
Date   Source Headline
3rd Jun 202612:22 pmRNSNet Asset Value(s)
2nd Jun 20262:04 pmRNSAppointment of Non-Executive Director
2nd Jun 20261:23 pmRNSNet Asset Value(s)
1st Jun 202612:24 pmRNSNet Asset Value(s)
29th May 20261:30 pmRNSNet Asset Value(s)
28th May 20263:31 pmRNSNet Asset Value(s)
27th May 20264:23 pmRNSNet Asset Value(s)
27th May 202611:57 amRNSMonthly Factsheet - April 2026
26th May 20265:24 pmRNSNet Asset Value(s)
22nd May 20262:06 pmRNSNet Asset Value(s)
21st May 20261:09 pmRNSNet Asset Value(s)
20th May 20263:20 pmRNSNet Asset Value(s)
19th May 20263:08 pmRNSNet Asset Value(s)
18th May 20261:36 pmRNSNet Asset Value(s)
15th May 20264:29 pmRNSPortfolio Management Update
15th May 20262:08 pmRNSNet Asset Value(s)
15th May 202612:42 pmRNSDistribution of Rump proceeds
14th May 20262:50 pmRNSNet Asset Value(s)
13th May 20262:19 pmRNSNet Asset Value(s)
13th May 20261:50 pmRNSHolding(s) in Company
12th May 20263:56 pmRNSHolding(s) in Company
12th May 20263:35 pmRNSDirector/PDMR Shareholding
12th May 20263:28 pmRNSNet Asset Value(s)
11th May 20262:45 pmRNSNet Asset Value(s)
8th May 20263:20 pmRNSNet Asset Value(s)
7th May 20264:28 pmRNSNet Asset Value(s)
7th May 20268:55 amRNSSubscription Rights Rump Placing
6th May 20265:19 pmRNSNet Asset Value(s)
6th May 20267:40 amRNSSubscription Rights for 2027
6th May 20267:28 amRNSSubscription Rights Results 2026
5th May 20264:50 pmRNSNet Asset Value(s)
1st May 20263:14 pmRNSNet Asset Value(s)
30th Apr 20264:08 pmRNSNet Asset Value(s)
29th Apr 20263:00 pmRNSNet Asset Value(s)
28th Apr 20262:52 pmRNSNet Asset Value(s)
28th Apr 202610:10 amRNS-RUpdate research from QuotedData
27th Apr 20262:55 pmRNSNet Asset Value(s)
24th Apr 20262:58 pmRNSNet Asset Value(s)
23rd Apr 20262:55 pmRNSNet Asset Value(s)
23rd Apr 202610:09 amRNSMonthly Factsheet- March 2026
22nd Apr 20261:38 pmRNSNet Asset Value(s)
21st Apr 20262:55 pmRNSNet Asset Value(s)
20th Apr 202612:20 pmRNSNet Asset Value(s)
17th Apr 20263:29 pmRNSNet Asset Value(s)
16th Apr 20262:35 pmRNSNet Asset Value(s)
16th Apr 202610:41 amRNSDirectors intent re subscription rights
15th Apr 20261:29 pmRNSNet Asset Value(s)
14th Apr 20261:11 pmRNSNet Asset Value(s)
14th Apr 20267:52 amRNSNet Asset Value(s)
10th Apr 20261:55 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.